- Home
- FDBC vs ACRS Comparison
FDBC vs ACRS Comparison
Compare FDBC & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FDBC | ACRS |
|---|---|---|
| Founded | 1902 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 262.3M | 311.0M |
| IPO Year | 2000 | 2015 |
Fundamental Metrics
Financial Performance| Metric | FDBC | ACRS |
|---|---|---|
| Price | $46.07 | $3.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.75 |
| AVG Volume (30 Days) | 4.6K | ★ 1.5M |
| Earning Date | 01-27-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.82% | N/A |
| EPS Growth | 35.00 | ★ 69.01 |
| EPS | ★ 4.86 | N/A |
| Revenue | N/A | ★ $1,683,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.24 |
| P/E Ratio | $9.27 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $37.00 | $1.09 |
| 52 Week High | $50.00 | $4.89 |
Technical Indicators
Market Signals| Indicator | FDBC | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 54.33 | 54.50 |
| Support Level | $44.69 | $3.16 |
| Resistance Level | $45.67 | $4.22 |
| Average True Range (ATR) | 1.50 | 0.26 |
| MACD | 0.26 | 0.01 |
| Stochastic Oscillator | 73.07 | 62.22 |
Price Performance
Historical ComparisonAbout FDBC Fidelity D & D Bancorp Inc.
Fidelity D & D Bancorp Inc is a bank holding company. Through its wholly-owned state-chartered commercial bank subsidiary, The Fidelity Deposit and Discount Bank (the Bank), it offers a full range of traditional banking services. The Bank has a personal and corporate trust department and also provides alternative financial and insurance products with asset management services. Its primary market areas are Lackawanna, Luzerne and Northampton Counties, Pennsylvania. The company's primary deposit products are demand deposits and interest-bearing time, money market and savings accounts. It offers a full array of loan products to meet the needs of retail and commercial customers. Company includes segments: Commercial and Industrial, Commercial Real Estate, Consumer, Residential Real Estate.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.